tiprankstipranks
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
US Market

Kymera Therapeutics (KYMR) Income Statement

Compare
218 Followers

Kymera Therapeutics Income Statement

Last quarter (Q3 2024), Kymera Therapeutics's total revenue was $3.74M, a decrease of -20.88% from the same quarter last year. In Q3, Kymera Therapeutics's net income was $-62.49M. See Kymera Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 78.59M$ 46.83M$ 72.83M$ 34.03M$ 2.93M
Gross Profit
$ -110.49M$ 43.85M$ 70.44M$ -28.07M$ 2.11M
Operating Expenses
$ 244.12M$ 208.08M$ 173.36M$ 80.34M$ 45.14M
Depreciation and Amortization
$ 3.56M$ 2.98M$ 2.40M$ 1.76M$ 825.00K
EBITDA
$ -143.20M$ -151.66M$ -97.64M$ -43.72M$ -40.38M
Operating Income
$ -165.53M$ -161.26M$ -100.53M$ -46.30M$ -42.20M
Other Income/Expenses
$ 18.57M$ 6.45M$ 313.00K$ 711.00K$ 959.00K
Pretax Income
$ -146.96M$ -154.81M$ -100.22M$ -45.59M$ -41.25M
Net Income
$ -146.96M$ -151.83M$ -98.00M$ -43.95M$ -41.29M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -2.52$ -2.82$ -2.04$ -2.53$ -0.93
Diluted EPS
$ -2.52$ -2.82$ -2.04$ -2.53$ -0.93
Weighted Average Shares Outstanding
58.37M 53.93M 47.99M 17.35M 44.53M
Weighted Average Shares Outstanding (Diluted)
58.37M 53.93M 47.99M 17.35M 44.53M
Currency in USD

Kymera Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis